Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IL6 receptor inhibitors: exploring the therapeutic potential across multiple diseases through drug target Mendelian randomization.

Frontiers in immunology - 1 Jan 2024

Fu Chong, Wang Longquan, Cai Wenjiao

Abstract excerpt

Background: High interleukin-6 levels correlate with diseases like cancer, autoimmune disorders, and infections. IL-6 receptor inhibitors (IL-6Ri), used for rheumatoid arthritis and COVID-19, may have wider uses. We apply drug-target Mendelian Randomization (MR) to study IL-6Ri's effects. Method: To simulate the effects of genetically blocking the IL-6R, we selected single nucleotide polymorphisms (SNPs) within...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arthritis, Rheumatoid
Share to Asthma
Share to COVID-19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to COVID-19 Drug Treatment

Share to Interleukin-6

Share to Mendelian Randomization Analysis

Share to Receptors, Interleukin-6

Share to SARS-CoV-2

Source

Open in PubMed Open full text

Identifiers

PMID: 39229261
DOI: 10.3389/fimmu.2024.1452849
PMCID: PMC11368790

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IL6 receptor inhibitors: exploring the therapeutic potential across multiple diseases through drug target Mendelian randomization.PMID 39229261Read ↗

Exploring the therapeutic potential of interleukin-6 receptor blockade in autoimmune diseases using drug target mendelian randomization.Semantic proximity Read ↗

Genetic perturbation of IL-6 receptor signaling pathway and risk of multiple respiratory diseasesSemantic proximity Read ↗

Exploring the therapeutic potential of interleukin-6 receptor blockade in cardiovascular disease treatment through Mendelian randomization.Semantic proximity Read ↗

Interleukins and rheumatoid arthritis: bi-directional Mendelian randomization investigation.Semantic proximity Read ↗

Genetically proxied IL-6 receptor inhibition is associated with increased risk of atopic dermatitis.Semantic proximity Read ↗

Exploring inflammatory bowel disease therapy targets through druggability genes: a Mendelian randomization study.Semantic proximity Read ↗

Genetic evidence for efficacy of targeting IL-2, IL-6, and TYK2 signaling in prevention of type 1 diabetes: A Mendelian randomization studySemantic proximity Read ↗

Differential Associations of Interleukin 6 Receptor Variant Across Genetic Ancestries and Implications for Targeted TherapiesSemantic proximity Read ↗

Genetically downregulated interleukin-6 signaling is associated with a favorable cardiometabolic profile: a phenome-wide association studySemantic proximity Read ↗

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.Semantic proximity Read ↗

Genetic evidence for efficacy of targeting IL-2, IL-6 and TYK2 signalling in the prevention of type 1 diabetes: a Mendelian randomisation study.Semantic proximity Read ↗

Cumulative Evidence for Associations Between Genetic Variants in Interleukin 6 Receptor Gene and Human Diseases and Phenotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.